News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Daniel J. George, MD, Duke Cancer Institute

Articles by Daniel J. George, MD, Duke Cancer Institute

Emerging Therapies for Advanced Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Radium-223 in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Genetic Testing in Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Impact of Clinical Data on the Treatment of mCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

The CARD and PROfound Trials for Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Differences Between AR-Targeted Therapy in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Overall Survival Data Presented at ASCO 2020 for nmCRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

FDA Approved Agents for Non-Metastatic CRPC

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Clinical Trials in the Community Setting for Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Data for Metastatic Castration-Sensitive Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Conventional Versus PSMA Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

PSMA-Targeted Imaging in Prostate Cancer

ByDaniel J. George, MD, Duke Cancer Institute,Tanya Dorff, MD, City of Hope Comprehensive Cancer Center,Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center,Benjamin H. Lowentritt, MD, FACS, Chesapeake Urology,Charles Ryan, MD, University of Minnesota

July 9th 2020

Latest Updated Articles

FDA Approved Agents for Non-Metastatic CRPC
July 9th 2020
Conventional Versus PSMA Imaging in Prostate Cancer
July 9th 2020
The CARD and PROfound Trials for Metastatic CRPC
July 9th 2020
Emerging Therapies for Advanced Prostate Cancer
July 9th 2020
Data for Metastatic Castration-Sensitive Prostate Cancer
July 9th 2020
Impact of Clinical Data on the Treatment of mCRPC
July 9th 2020

Trending on OncLive

In Vivo CD19/CD20 CAR T-Cell Therapy Is Safe, Yields 100% ORR at Phase 1, Dose Level 2 in R/R Non-Hodgkin Lymphomas

Subcutaneous Blinatumomab Yields High Efficacy Rates in R/R Ph+ B-ALL

Rocbrutinib Shows Durable Efficacy in BTK Inhibitor–Pretreated R/R Mantle Cell Lymphoma

Tacabrutideg Is Tolerable and Shows Efficacy Signals Across BTK Inhibitor–Naive CLL and Other B-Cell Malignancies

Real-World Analysis Reveals Liso-Cel Elicits High Response Rates in R/R Mantle Cell Lymphoma